Project Grant R01CA307210
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $580K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $131,933 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support spatial and functional profiling of tumor evolution trajectories and microenvironment interactions in VHL-driven renal cancers. The project applies spatially resolved transcriptomics, genomic engineering, and multi-omics methodologies to create a comprehensive spatial atlas of treatment-resistant clear cell renal cell...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $586,101 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in the bone tumor microenvironment of prostate cancer bone metastasis. The research addresses immune checkpoint therapy resistance in bone metastatic prostate cancer by characterizing how the bone tumor microenvironment conditions PMN-MDSCs to...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $559,999 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on modulating hypoxia-activated stromal programs to potentiate CAR-T cell therapy in kidney cancer. Work is performed in Houston, Texas, with a period of performance through August 31, 2028. The award funds translational oncology research integrating immunotherapy and tumor microenvironment...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,739 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to unravel the molecular mechanisms of immunotherapy-associated myocarditis. The research investigates how immune checkpoint inhibitors, which enhance anti-tumor immune responses in cancer treatment, trigger myocarditis—inflammation of the heart that carries mortality rates up to 50 percent. The project uses mouse models...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $616,624 to The Medical University of South Carolina on May 18, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying renal cell carcinoma sensitivity to BCL-XL inhibition in SETD2-deficient tumors. The project explores how loss of SETD2, a histone methyltransferase frequently mutated in renal cell carcinoma,...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...